UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

NOTICE OF ALLOWANCE AND FEE(S) DUE

2202

7590

03/19/2008

BIRCH STEWART KOLASCH & BIRCH PO BOX 747 FALLS CHURCH, VA 22040-0747 EXAMINER

RAMIREZ, DELIA M

ART UNIT PAPER NUMBER

1652

DATE MAILED: 03/19/2008

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/507,132	09/10/2004	Koichiro Kaku	1254-0258PUS1	2346

TITLE OF INVENTION: SCYTALONE DEHYDROGENASE GENE SHOWING TOLERANCE TO AGRICULTURAL PESTICIDE

APPLN. TYPE	SMALL ENTITY	ISSUE FEE DUE	PUBLICATION FEE DUE	PREV. PAID ISSUE FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	NO	\$1440	\$300	\$0	\$1740	06/19/2008

THE APPLICATION IDENTIFIED ABOVE HAS BEEN EXAMINED AND IS ALLOWED FOR ISSUANCE AS A PATENT. PROSECUTION ON THE MERITS IS CLOSED. THIS NOTICE OF ALLOWANCE IS NOT A GRANT OF PATENT RIGHTS. THIS APPLICATION IS SUBJECT TO WITHDRAWAL FROM ISSUE AT THE INITIATIVE OF THE OFFICE OR UPON PETITION BY THE APPLICANT. SEE 37 CFR 1.313 AND MPEP 1308.

THE ISSUE FEE AND PUBLICATION FEE (IF REQUIRED) MUST BE PAID WITHIN THREE MONTHS FROM THE MAILING DATE OF THIS NOTICE OR THIS APPLICATION SHALL BE REGARDED AS ABANDONED. THIS STATUTORY PERIOD CANNOT BE EXTENDED. SEE 35 U.S.C. 151. THE ISSUE FEE DUE INDICATED ABOVE DOES NOT REFLECT A CREDIT FOR ANY PREVIOUSLY PAID ISSUE FEE IN THIS APPLICATION. IF AN ISSUE FEE HAS PREVIOUSLY BEEN PAID IN THIS APPLICATION (AS SHOWN ABOVE), THE RETURN OF PART B OF THIS FORM WILL BE CONSIDERED A REQUEST TO REAPPLY THE PREVIOUSLY PAID ISSUE FEE TOWARD THE ISSUE FEE NOW DUE.

HOW TO REPLY TO THIS NOTICE:

I. Review the SMALL ENTITY status shown above.

If the SMALL ENTITY is shown as YES, verify your current SMALL ENTITY status:

A. If the status is the same, pay the TOTAL FEE(S) DUE shown above.

B. If the status above is to be removed, check box 5b on Part B - Fee(s) Transmittal and pay the PUBLICATION FEE (if required) and twice the amount of the ISSUE FEE shown above, or

If the SMALL ENTITY is shown as NO:

A. Pay TOTAL FEE(S) DUE shown above, or

B. If applicant claimed SMALL ENTITY status before, or is now claiming SMALL ENTITY status, check box 5a on Part B - Fee(s) Transmittal and pay the PUBLICATION FEE (if required) and 1/2 the ISSUE FEE shown above.

II. PART B - FEE(S) TRANSMITTAL, or its equivalent, must be completed and returned to the United States Patent and Trademark Office (USPTO) with your ISSUE FEE and PUBLICATION FEE (if required). If you are charging the fee(s) to your deposit account, section "4b" of Part B - Fee(s) Transmittal should be completed and an extra copy of the form should be submitted. If an equivalent of Part B is filed, a request to reapply a previously paid issue fee must be clearly made, and delays in processing may occur due to the difficulty in recognizing the paper as an equivalent of Part B.

III. All communications regarding this application must give the application number. Please direct all communications prior to issuance to Mail Stop ISSUE FEE unless advised to the contrary.

IMPORTANT REMINDER: Utility patents issuing on applications filed on or after Dec. 12, 1980 may require payment of maintenance fees. It is patentee's responsibility to ensure timely payment of maintenance fees when due.

PART B - FEE(S) TRANSMITTAL

Complete and send this form, together with applicable fee(s), to: Mail Mail Stop ISSUE FEE

Commissioner for Patents P.O. Box 1450

Alexandria, Virginia 22313-1450 (571)-273-2885 or <u>Fax</u>

INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 5 should be completed where appropriate. All further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as indicated unless corrected below or directed otherwise in Block 1, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for

maintenance fee notifications. Note: A certificate of mailing can only be used for domestic mailings of the CURRENT CORRESPONDENCE ADDRESS (Note: Use Block 1 for any change of address) Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission. 2292 7590 03/19/2008 Certificate of Mailing or Transmission BIRCH STEWART KOLASCH & BIRCH I hereby certify that this Fee(s) Transmittal is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop ISSUE FEE address above, or being facsimile transmitted to the USPTO (571) 273-2885, on the date indicated below. PO BOX 747 FALLS CHURCH, VA 22040-0747 (Depositor's name (Signature (Date APPLICATION NO. FILING DATE FIRST NAMED INVENTOR ATTORNEY DOCKET NO. CONFIRMATION NO. 10/507,132 09/10/2004 Koichiro Kaku 1254-0258PUS1 2346 TITLE OF INVENTION: SCYTALONE DEHYDROGENASE GENE SHOWING TOLERANCE TO AGRICULTURAL PESTICIDE APPLN. TYPE SMALL ENTITY ISSUE FEE DUE PUBLICATION FEE DUE PREV. PAID ISSUE FEE TOTAL FEE(S) DUE DATE DUE nonprovisional NO \$1440 \$300 \$0 \$1740 06/19/2008 **EXAMINER** ART UNIT CLASS-SUBCLASS RAMIREZ, DELIA M 1652 435-252300 1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.363). 2. For printing on the patent front page, list (1) the names of up to 3 registered patent attorneys or agents OR, alternatively, ☐ Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached. (2) the name of a single firm (having as a member a ☐ "Fee Address" indication (or "Fee Address" Indication form PTO/SB/47; Rev 03-02 or more recent) attached. Use of a Customer Number is required. registered attorney or agent) and the names of up to 2 registered patent attorneys or agents. If no name is listed, no name will be printed. 3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type) PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. If an assignee is identified below, the document has been filed for recordation as set forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filing an assignment. (A) NAME OF ASSIGNEE (B) RESIDENCE: (CITY and STATE OR COUNTRY) 4b. Payment of Fee(s): (Please first reapply any previously paid issue fee shown above) 4a. The following fee(s) are submitted: lssue Fee A check is enclosed. Publication Fee (No small entity discount permitted) Payment by credit card. Form PTO-2038 is attached. The Director is hereby authorized to charge the required fee(s), any deficiency, or credit any overpayment, to Deposit Account Number ______ (enclose an extra copy of this fo Advance Order - # of Copies _ (enclose an extra copy of this form). 5. Change in Entity Status (from status indicated above) a. Applicant claims SMALL ENTITY status. See 37 CFR 1.27. ■ b. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2). NOTE: The Issue Fee and Publication Fee (if required) will not be accepted from anyone other than the applicant; a registered attorney or agent; or the assignee or other party in interest as shown by the records of the United States Patent and Trademark Office. Authorized Signature Date Typed or printed name Registration No. This collection of information is required by 37 CFR 1.311. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.

PTOL-85 (Rev. 08/07) Approved for use through 08/31/2010.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450

P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/507,132	09/10/2004	Koichiro Kaku	1254-0258PUS1	2346
2292 75	590 03/19/2008		EXAM	INER
BIRCH STEWART KOLASCH & BIRCH			RAMIREZ, DELIA M	
PO BOX 747			ART UNIT	PAPER NUMBER
FALLS CHURCH	, VA 22040-0747		1652	
			DATE MAIL ED: 03/10/200	8

Determination of Patent Term Adjustment under 35 U.S.C. 154 (b)

(application filed on or after May 29, 2000)

The Patent Term Adjustment to date is 260 day(s). If the issue fee is paid on the date that is three months after the mailing date of this notice and the patent issues on the Tuesday before the date that is 28 weeks (six and a half months) after the mailing date of this notice, the Patent Term Adjustment will be 260 day(s).

If a Continued Prosecution Application (CPA) was filed in the above-identified application, the filing date that determines Patent Term Adjustment is the filing date of the most recent CPA.

Applicant will be able to obtain more detailed information by accessing the Patent Application Information Retrieval (PAIR) WEB site (http://pair.uspto.gov).

Any questions regarding the Patent Term Extension or Adjustment determination should be directed to the Office of Patent Legal Administration at (571)-272-7702. Questions relating to issue and publication fee payments should be directed to the Customer Service Center of the Office of Patent Publication at 1-(888)-786-0101 or (571)-272-4200.

	Art Unit amirez 1652 cover sheet with the correspondence address NS) CLOSED in this application. If not included propriate communication will be mailed in due course. THIS application is subject to withdrawal from issue at the initiative 1308. C. § 119(a)-(d) or (f). red. red in Application No re been received in this national stage application from the nunication to file a reply complying with the requirements
Polia M. R The MAILING DATE of this communication appears on the All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAIN NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1. ☑ This communication is responsive to 1/18/2007. 2. ☑ The allowed claim(s) is/are 1-3,5,6,12,13 and 17-19. 3. ☑ Acknowledgment is made of a claim for foreign priority under 35 U.S. a) ☑ All b) ☐ Some* c) ☐ None of the: 1. ☑ Certified copies of the priority documents have been received: 2. ☐ Certified copies of the priority documents have been received: 3. ☐ Copies of the certified copies of the priority documents have been received: International Bureau (PCT Rule 17.2(a)). * Certified copies not received: Applicant has THREE MONTHS FROM THE "MAILING DATE" of this commoted below. Failure to timely comply will result in ABANDONMENT of this THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.	Art Unit amirez 1652 cover sheet with the correspondence address NS) CLOSED in this application. If not included propriate communication will be mailed in due course. THIS application is subject to withdrawal from issue at the initiative 1308. C. § 119(a)-(d) or (f). red. red in Application No re been received in this national stage application from the nunication to file a reply complying with the requirements
The MAILING DATE of this communication appears on the All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAI herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other app NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1. ☐ This communication is responsive to 1/18/2007. 2. ☐ The allowed claim(s) is/are 1-3,5,6,12,13 and 17-19. 3. ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S. a) ☐ All b) ☐ Some* c) ☐ None of the: 1. ☐ Certified copies of the priority documents have been receiv 2. ☐ Certified copies of the priority documents have been receiv 3. ☐ Copies of the certified copies of the priority documents have International Bureau (PCT Rule 17.2(a)). * Certified copies not received: Applicant has THREE MONTHS FROM THE "MAILING DATE" of this comm noted below. Failure to timely comply will result in ABANDONMENT of this THIS THREE-MONTH PERIOD IS NOT EXTENDABLE. 4. ☐ A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the	cover sheet with the correspondence address NS) CLOSED in this application. If not included propriate communication will be mailed in due course. THIS is application is subject to withdrawal from issue at the initiative 1308. C. § 119(a)-(d) or (f). Yed. Yed in Application No The been received in this national stage application from the intuition to file a reply complying with the requirements
The MAILING DATE of this communication appears on the All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAI herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other app NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1. ☐ This communication is responsive to 1/18/2007. 2. ☐ The allowed claim(s) is/are 1-3,5,6,12,13 and 17-19. 3. ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S. a) ☐ All b) ☐ Some* c) ☐ None of the: 1. ☐ Certified copies of the priority documents have been receiv 2. ☐ Certified copies of the priority documents have been receiv 3. ☐ Copies of the certified copies of the priority documents have International Bureau (PCT Rule 17.2(a)). * Certified copies not received: Applicant has THREE MONTHS FROM THE "MAILING DATE" of this comm noted below. Failure to timely comply will result in ABANDONMENT of this THIS THREE-MONTH PERIOD IS NOT EXTENDABLE. 4. ☐ A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the	cover sheet with the correspondence address NS) CLOSED in this application. If not included propriate communication will be mailed in due course. THIS is application is subject to withdrawal from issue at the initiative 1308. C. § 119(a)-(d) or (f). Yed. Yed in Application No The been received in this national stage application from the intuition to file a reply complying with the requirements
2. ☑ The allowed claim(s) is/are 1-3,5,6,12,13 and 17-19. 3. ☑ Acknowledgment is made of a claim for foreign priority under 35 U.S. a) ☑ All b) ☐ Some* c) ☐ None of the: 1. ☑ Certified copies of the priority documents have been received: 2. ☐ Certified copies of the priority documents have been received: 3. ☐ Copies of the certified copies of the priority documents have been received: International Bureau (PCT Rule 17.2(a)). * Certified copies not received: Applicant has THREE MONTHS FROM THE "MAILING DATE" of this commoted below. Failure to timely comply will result in ABANDONMENT of this THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.	ved. ved in Application No ve been received in this national stage application from the
 3. Acknowledgment is made of a claim for foreign priority under 35 U.S. a) All b) Some* c) None of the: Certified copies of the priority documents have been received. Certified copies of the priority documents have been received. Copies of the certified copies of the priority documents have International Bureau (PCT Rule 17.2(a)). * Certified copies not received: Applicant has THREE MONTHS FROM THE "MAILING DATE" of this commoted below. Failure to timely comply will result in ABANDONMENT of this THIS THREE-MONTH PERIOD IS NOT EXTENDABLE. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the 	ved. ved in Application No ve been received in this national stage application from the
a) ☑ All b) ☐ Some* c) ☐ None of the: 1. ☑ Certified copies of the priority documents have been received. 2. ☐ Certified copies of the priority documents have been received. 3. ☐ Copies of the certified copies of the priority documents have International Bureau (PCT Rule 17.2(a)). * Certified copies not received: Applicant has THREE MONTHS FROM THE "MAILING DATE" of this commended below. Failure to timely comply will result in ABANDONMENT of this THIS THREE-MONTH PERIOD IS NOT EXTENDABLE. 4. ☐ A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the	ved. ved in Application No ve been received in this national stage application from the
* Certified copies not received: Applicant has THREE MONTHS FROM THE "MAILING DATE" of this comm noted below. Failure to timely comply will result in ABANDONMENT of this THIS THREE-MONTH PERIOD IS NOT EXTENDABLE. 4. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the	
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this comm noted below. Failure to timely comply will result in ABANDONMENT of this THIS THREE-MONTH PERIOD IS NOT EXTENDABLE. 4. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the	
, ,	
5. CORRECTED DRAWINGS (as "replacement sheets") must be submitt	•
(a) ☐ including changes required by the Notice of Draftsperson's Patent	
1) ☐ hereto or 2) ☐ to Paper No./Mail Date .	
(b) ☐ including changes required by the attached Examiner's Amendment Paper No./Mail Date Identifying indicia such as the application number (see 37 CFR 1.84(c)) should each sheet. Replacement sheet(s) should be labeled as such in the header ac	d be written on the drawings in the front (not the back) of
DEPOSIT OF and/or INFORMATION about the deposit of BIOL attached Examiner's comment regarding REQUIREMENT FOR THE D	OGICAL MATERIAL must be submitted. Note the
Attachment(s) 1. ☐ Notice of References Cited (PTO-892) 5	☐ Notice of Informal Patent Application
	☐ Interview Summary (PTO-413),
	Paper No./Mail Date ☑ Examiner's Amendment/Comment
of Biological Material	☑ Examiner's Statement of Reasons for Allowance☐ Other

Art Unit: 1652

DETAILED ACTION

Status of the Application

Claims 1-3, 5-8, 12-13, 17-19 are pending.

Amendment of claims 1, 5, 12, 17, 19 and cancellation of claims 4, 9-11, 14-16, 20-21 as submitted in a communication filed on 1/18/2008 are acknowledged.

In a telephone conversation with Mr. Paul Pyla on 3/5/2008, an agreement was reached to amend claims 1, 5, 6, 18, 19 and cancel non-elected claims 7-8 to place the application in condition for allowance.

Examiner's Amendment

- 1. An extension of time under 37 CFR 1.136(a) is required in order to make an examiner's amendment which places this application in condition for allowance. During a telephone conversation conducted on 3/5/2008, Mr. Paul Pyla requested an extension of time for 2 MONTH(S) and authorized the Director to charge Deposit Account No. 02-2448 the required fee of \$ 460.00 for this extension and authorized the following examiner's amendment. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.
- 2. An Examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.
- 3. Authorization for this Examiner's amendment was given in a telephone interview with Mr. Paul Pyla on 3/5/2008.
- 4. Please cancel non-elected claims 7-8.
- 5. Please replace claims 1, 5, 6, 18 and 19 as follows:

Art Unit: 1652

1. An isolated or purified gene coding for either one of the following proteins (a) or (b):

- (a) a protein consisting of the amino acid sequence of SEQ ID NO: 2; or
- (b) a protein consisting of an amino acid sequence wherein said amino acid sequence is a variant of SEQ ID NO: 2 which differs from SEQ ID NO: 2 solely by deletion, substitution or addition of 1 to 10 amino acids in SEQ ID NO: 2, wherein the amino acid at the position corresponding to position 75 of SEQ ID NO: 2 is methionine, and wherein said protein has scytalone dehydratase activity in the presence of a scytalone dehydratase inhibitor.
- 5. A recombinant vector comprising a gene coding for either one of the following proteins (a) or (b):
 - (a) a protein consisting of the amino acid sequence of SEQ ID NO: 2; or
 - (b) a protein consisting of an amino acid sequence wherein said amino acid sequence is a variant of SEQ ID NO: 2 which differs from SEQ ID NO: 2 solely by deletion, substitution or addition of 1 to 10 amino acids in SEQ ID NO: 2, wherein the amino acid at the position corresponding to position 75 of SEQ ID NO: 2 is methionine, and wherein said protein has scytalone dehydratase activity in the presence of a scytalone dehydratase inhibitor.
- 6. An isolated transformed cell obtained by transformation with the recombinant vector of claim 5.

Art Unit: 1652

18. An isolated transformed cell obtained by transformation with the recombinant vector of claim 17.

19. An isolated or purified gene coding for a protein consisting of an amino acid sequence wherein said amino acid sequence is a variant of SEQ ID NO: 2 which differs from SEQ ID NO: 2 solely by deletion, substitution or addition of 1 to 10 amino acids in SEQ ID NO: 2, wherein the amino acid at the position corresponding to position 75 of SEQ ID NO: 2 is methionine, and wherein said protein has scytalone dehydratase activity in the presence of a scytalone dehydratase inhibitor.

Reasons for Allowance

6. The following is an Examiner's statement of reasons for allowance. Although the prior art discloses a gene encoding a scytalone dehydratase which comprises all of SEQ ID NO: 2 except for an amino acid substitution at position 75 (Motoyama et al., cited in previous Office actions), the Examiner has found no teaching or suggestion in the prior art directed to a gene encoding the protein of SEQ ID NO: 2 or a variant of said protein having scytalone dehydratase activity in the presence of a scytalone dehydratase inhibitor, wherein the amino acid corresponding to position 75 of SEQ ID NO: 2 is a methionine. Therefore, claims 1-3, 5-6, 12-13, 17-19, directed to (1) nucleic acids encoding (a) the polypeptide of SEQ ID NO: 2, (b) a variant of the polypeptide of SEQ ID NO: 2 having scytalone dehydratase activity wherein said variant differs from the polypeptide of SEQ ID NO: 2 solely by 1-10 amino acid modifications and wherein the amino acid corresponding to position 75 of SEQ ID NO: 2 is methionine, (2) vectors comprising the nucleic acids of (1), and (3) isolated host cells comprising said vectors, are allowable over the prior art of record.

Art Unit: 1652

Conclusion

7. Claims 1-3, 5-6, 12-13, 17-19 are allowed.

8. Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such

submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

9. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Delia M. Ramirez whose telephone number is (571) 272-0938. The examiner can normally be reached on Monday-Friday from 8:30 AM to 5:00 PM. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Dr. Nashaat Nashed can be reached on (571) 272-0934. Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (571) 272-1600.

/Delia M. Ramirez/

Delia M. Ramirez, Ph.D. Primary Patent Examiner Art Unit 1652

DR March 17, 2008